What is the treatment for a newborn baby with Hypoxic-Ischemic Encephalopathy (HIE)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Neonatal Hypoxic-Ischemic Encephalopathy (HIE)

Therapeutic hypothermia is the standard of care and must be initiated within 6 hours of birth for term or near-term infants (≥36 weeks gestation) with moderate-to-severe HIE, as it reduces death or major neurodevelopmental disability by 22-33%. 1, 2

Patient Selection Criteria

Infants must meet ALL of the following criteria to qualify for therapeutic hypothermia 1, 3:

  • Gestational age ≥36-37 weeks 1, 3
  • Evidence of perinatal asphyxia, defined as:
    • Apgar score ≤5 at 10 minutes, OR
    • Need for resuscitation at 10 minutes, OR
    • Severe acidosis (pH <7.0 or base deficit ≥12-16 mmol/L) 3, 4
  • Moderate-to-severe encephalopathy on clinical examination using modified Sarnat criteria with at least 3 of 6 categories (level of consciousness, spontaneous activity, posture, tone, primitive reflexes, autonomic system) scored in the moderate or severe range 3, 4
  • Age <6 hours from birth 5, 1, 2

Therapeutic Hypothermia Protocol

Cooling Methods

Both whole body cooling and selective head cooling are equally effective 5, 1:

  • Whole body cooling: Target core temperature 33-34°C 5, 1, 3
  • Selective head cooling: Target core temperature 34.5°C 6

Critical Timing and Duration

  • Initiate within 6 hours of birth - efficacy decreases significantly after this window 5, 1, 2
  • Continue for 72 hours of continuous cooling 5, 1, 3
  • Rewarm slowly over at least 4 hours at approximately 0.5°C per hour 5, 1, 3

Temperature Monitoring

Avoid temperatures below 32°C as they are less neuroprotective, and temperatures below 30°C cause severe complications 6. Core temperature must be continuously monitored with strict control, targeting 33.5°C ± 0.5°C during passive cooling for transport 4.

Required Facility Capabilities

Cooling should ONLY be conducted in neonatal intensive care facilities with multidisciplinary capabilities 5, 1, 3:

  • Intravenous therapy 1, 3
  • Respiratory support and mechanical ventilation 1, 3
  • Continuous pulse oximetry 1, 3
  • Antibiotics and anticonvulsant medications 1, 3
  • Transfusion services 1
  • Radiology including ultrasound 1
  • Pathology testing 1

Supportive Care During Cooling

Respiratory Management

  • Maintain adequate ventilation and oxygenation 3
  • Target PaCO₂ of 4.5-5.0 kPa 1
  • Start resuscitation with room air (21% oxygen) for term infants, titrating based on pulse oximetry 3

Cardiovascular Support

  • Maintain systolic blood pressure >110 mmHg 1
  • Monitor for and treat hypotension, which is a known complication of cooling 5, 3
  • Increased need for inotropic support may occur 3

Metabolic Management

  • Initiate intravenous glucose infusion as soon as practical to avoid hypoglycemia 5, 3
  • Monitor for thrombocytopenia, a known adverse effect of cooling 5, 3

Seizure Management

  • Do NOT administer prophylactic antiepileptic drugs 4
  • Implement continuous EEG or amplitude-integrated EEG monitoring as soon as possible to accurately diagnose seizures 4
  • Electrographic seizures are rare in the first few hours after birth if the insult occurred during labor and delivery 4

Expected Outcomes

Overall Benefit

  • Number needed to treat is 5-9 infants to prevent one case of death or major neurodevelopmental disability 5, 1, 2
  • Absolute risk reduction of 151 fewer cases of death or neurodevelopmental impairment per 1000 infants treated at 18-24 months 1, 2

Specific Neurological Benefits

  • 48% reduction in cerebral palsy (RR 0.52; 95% CI 0.37-0.72) 1, 2
  • 52% reduction in blindness (RR 0.48; 95% CI 0.22-1.03) 1, 2
  • 58% reduction in deafness (RR 0.42; 95% CI 0.21-0.82) 1, 2

Effectiveness by HIE Severity

  • Moderate HIE: 33% reduction in death or major neurodevelopmental disability (RR 0.67; 95% CI 0.56-0.81) 1, 2
  • Severe HIE: 17% reduction (RR 0.83; 95% CI 0.74-0.92) 1, 2

Critical Pitfalls to Avoid

  • Never initiate cooling beyond 6 hours of life - efficacy decreases significantly after this window 1, 3
  • Never rewarm rapidly - rewarming must occur over at least 4 hours to prevent complications including metabolic instability 5, 1, 3
  • Never attempt therapeutic hypothermia without proper monitoring equipment and trained staff 3
  • Never implement cooling in facilities lacking multidisciplinary care capabilities 5, 1
  • Avoid temperatures below 32°C as neuroprotection decreases, and avoid temperatures below 30°C which cause severe complications 6

Transport Considerations

If an infant qualifies or there is concern for HIE, transfer to a center capable of performing therapeutic hypothermia should be initiated immediately 4. During passive cooling for transport, core temperature must be closely monitored with a target of 33.5°C ± 0.5°C 4.

Long-term Follow-up

All treated infants should be followed longitudinally to assess neurodevelopmental outcomes 5.

References

Guideline

Therapeutic Hypothermia in Hypoxic-Ischemic Encephalopathy (HIE)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Therapeutic Hypothermia for Neonatal Hypoxic Ischemic Encephalopathy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Birth Asphyxia in NICU

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.